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Purpose
Intratumoral immune activation can induce systemic
immunity and anti-tumor activity. Imiquimod is a cream-
formulated, TLR-7 agonist that is FDA-approved for the
treatment of non-melanoma skin cancers, but has limited
activity against melanoma. In the current study, we studied
the anti-tumor activity and mechanism of action of a novel
injectable TLR 7/8 dual agonist, 3M-052, which remains at
the site of injection to avoid systemic distribution.
Experimental design
Mice bearing established B16 melanomas were treated
intratumorally with 3M-052 or vehicle. The mechanistic
contribution of individual cell types and molecules to
the anti-tumor effect was determined using genetically
engineered mice and antibody blockades. Immune cell
infiltrates were analyzed by flow cytometry.
Results
Intratumoral administration of 3M-052 generated sys-
temic anti-tumor immunity and suppressed both injected
and distant uninjected wild-type B16.F10 melanomas.
Treated tumors showed increased level of CCL2 chemo-
kines and CCL2 dependent infiltration of M1 phenotype-
shifted macrophages which could kill tumor cells directly
through production of nitric oxide. CD8+ T cells, B cells,
Type I IFN, IFN-g, and pDCs contributed to efficient
tumor suppression whereas perforin, NK cells and CD4
T cells were not required.
Conclusion
Induction of effective innate and tumor specific adaptive
immunity by intratumoral treatment of TLR7/8 agonist,
3M-052 is a promising approach for the treatment of
metastatic cancer.
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